Why the Army didn't finish testing the Sig Sauer P320 during the XM17 competition
First, let's lay the groundwork for how military acquisitions, specifically pistols, work. And no, it's not as simple as 'lowest bidder.'
The military puts out a requirement for a piece of equipment, and manufacturers submit their products for consideration. These submissions are judged on whether or not they meet the basic requirements in the first phase of the competition. Following this initial down select, submissions that pass phase one are then competed in destructive testing to determine which is truly best. In the event of a draw, competitive bidding is then used to determine a winner.
The XM17 MHS program was designed to replace the Beretta M9 pistol. In 1985, the Beretta won the XM9 competition to replace the M1911 pistol. So, how did that competition go?
Eight different pistols were submitted and subjected to phase one testing. Only the Italian Beretta 92F and SIG Sauer's P226, designed and built by the Swiss-German SIG Sauer and imported by Saco Defense for the XM9 trials, passed and advanced to phase two. Through destructive testing of 35,000 rounds per pistol, the 92F and P226 performed similarly and exceeded the requirements set forth by the Army. Moreover, they outperformed the M1911 they were meant to replace.
At that point, both pistols proved that they could serve the U.S. military well. Although SIG Sauer priced individual pistols lower, Beretta's overall price was lower after factoring in spare parts and magazines, and the 92F became the M9. Early models experienced slide cracks due to improper loading of military 9mm ammunition, but Beretta's design was sound.
So, why did the Army want a new handgun just 30 years later?
While the Beretta performed exceptionally during testing, troops had issues with it. First, the Army contracted spare magazines that did not perform well in the sandy environment of the Middle East. Second, 9mm ball ammunition lacked the stopping power to put down threats effectively. Third, the M9's size made it difficult for smaller troops to handle, and it was easy to accidentally engage the safety when racking the slide.
The Army also wanted to incorporate technological advances with a new pistol. As the name states, the Modular Handgun System needed to be configurable for different troops and different missions. Among the requirements were the ability to mount a light/laser, attach a suppressor, and adjust the grip to fit various hand sizes.
As the contract holder, Beretta offered the M9A3 to address some of these issues as well as upgrade existing stocks of M9s. While upgrades corrected issues with the original M16 rifle and M4 carbine, the Army was determined to acquire a new pistol and rejected Beretta.
In 2015, the Army released the Request for Proposals and started testing the 12 submitted pistols the following year. After phase one testing, the SIG Sauer and Glock submissions were the only ones that made it past the down select. Phase two destructive testing began, but was stopped at 12,500 rounds, half of the 25,000-round required service life. Moreover, destructive testing called for the pistols to fire up to 35,000 rounds to test reliability.
Glock protested the Army's premature selection of the Sig Sauer submission and asked that testing resume. An investigation by the Government Accountability Office found that 'Sig Sauer's full-sized handgun had a higher stoppage rate than Glock's handgun, and there may have been other problems with the weapon's accuracy.'
The investigation also noted that the Army redacted the results of Sig's compact handgun. Sig submitted two handgun frames in three different grip sizes with a swappable trigger unit, while Glock submitted one handgun with interchangeable backstraps to meet the Army's modularity requirements.
In the end, Glock's protest was denied.
'[T]here is no correlating superior performance factor for Glock, as compared to Sig Sauer's, to support paying that premium. Consequently, I cannot justify paying a price premium of 37% for the Glock submission, even as a second award,' wrote Susan Poling in the GAO report. She did note the investigation uncovered 'evaluation errors' by the Army, but could not justify paying more for the Glock.
The short of it is that Sig Sauer's price to the government was so low that the Army felt that it had a good enough pistol at a great price. So, testing was stopped and did not resume.
Formally adopted as the full-size XM17 and compact XM18, the Sig underwent Product Verification Testing in FY17, which found that the gun could discharge when dropped. An Engineering Change Proposal by Sig Sauer corrected this with lightweight components in the trigger group mechanism.
While Sig Sauer made the ECP changes to all military pistols, it was offered as a Voluntary Upgrade Program on the civilian market. The FY17 PVT also revealed issues with double-ejections, where unfired rounds were ejected from the gun, as well as a high rate of stoppages with ball ammunition.
Product Verification Testing in FY18 with an upgraded configuration of the MHS resulted in reduced stoppages with ball ammunition. Interestingly, the pistols performed better with jacketed hollow-point ammunition. The PVT also showed no issues with accuracy, as addressed in the GAO report. After this, the Army concluded that the MHS 'meets or exceeds requirements for accuracy, lethality, ergonomics, and safety.'
The Sig Sauer P320 was arguably awarded the MHS contract prematurely. Issues following the weapon's adoption by the Army may have been revealed during trial testing. Additionally, reports of P320s firing uncommanded have resulted in a recommendation for a Marine Corps engineering review and the disuse of the M18 by an Air Force command following the death of an airman.
'SIG SAUER followed all acquisition regulations and solicitation protocols related to the competitive process,' Sig Sauer's Vice President of Marketing Jason Wright told WATM. 'The decision to select the P320 as the winner of the XM17 MHS competition prior to the conclusion of phase two testing was exclusively determined by the U.S. Army.'
We Are The Mighty reached out to the Army for comment on the MHS competition and M17/M18 acquisition following these incidents and did not receive a response.
Featured
Weapons
Sig Sauer's P320 banned by Chicago Police Department and other law enforcement agencies
By Miguel Ortiz
Feature
SIG Sauer's legal battles and why the XM7 might not replace the M4 SIG Sauer's legal battles and why the XM7 might not replace the M4
By Miguel Ortiz
Solve the daily Crossword

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Targa Resources Signals Steady Leadership and Smart Liquidity Moves Amid Market Volatility
Targa Resources Corp. (NYSE:TRGP) is one of the best commodity stocks to buy, and here's why recent moves show they're not complacent. On August 1, 2025, the company quietly ushered in a leadership transition in its logistics arm, announcing that D. Scott Pryor will retire next March and internal veteran Benjamin J. Branstetter will step into the role. That internal elevation speaks volumes about continuity and confidence in the leadership bench. Before that, on July 28, the firm took care of business by extending its $600 million receivables securitization facility through August 2026, keeping a reliable, cost-effective liquidity line alive without rocking the economics. That kind of responsible financial housekeeping ensures operational flexibility and reflects sound planning amid energy market complexities. QiuJu Song/ Targa Resources Corp. (NYSE:TRGP) is a major midstream energy player in North America, owning and operating gathering, processing, transportation, and storage infrastructure for natural gas and natural gas liquids. The company enables energy delivery across key U.S. shale basins through its integrated midstream value chain. While we acknowledge the potential of TRGP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
The Twins are No Longer for Sale
In the latest middle finger to fans, this morning the Minnesota Twins posted the following letter on all their social media channels, coming directly from the Pohlads themselves. The key takeaway is the following quote: After a detailed process, our family will remain the principal owners of the Minnesota Twins… We are in the process of adding two significant limited partnership groups, each of whom will bring a wealth of experience and share our family values. Guess what folks? After all the hemming, hawing, and Justin Ishbia-induced teasing, we're stuck with what has turned into one of the worst ownership groups in baseball, which is saying a lot these days. While they're bringing in new investors to presumably add some more cash to the business, there is nothing in the history of Pohlad family ownership that suggests that money will be invested into the team rather than pocketed by greedy billionaires. This era of Twins baseball has been an unmitigated disaster since the high of the 2023 playoffs, which John Foley already recapped extensively. While there are definite arguments for a soft reset after missing the playoffs for (likely) four of the last five seasons, Derek Falvey, with a mandate from the Pohlads to shed salary, instead traded away their biggest free agent signing in franchise history, their five best relievers including two of the best in Twins history, and signs are pointing toward trades for Joe Ryan, Pablo Lopez, and Ryan Jeffers in the near future. I would love to be proven wrong, but this has moved from reset to a full-on rebuild, which becomes more likely with the Pohlads remaining in control for the foreseeable future. All this comes while team owner Joe Pohlad has refused to speak to the press or the fans. Joe is expected to speak to the press at some point today where he will likely dodge any and all relevant questions around the blowing up of a once-competitive team, but as we've learned with Joe Pohlad in particular, it's better to look at his actions rather than his words. This is the same man that said they would be open to increasing payroll after their success in 2023, just to shed $30M instead, directly leading to their collapse in the proceeding two seasons. In a world where billionaires are rapidly destroying our tax dollars, constitutional rights, and social safety nets, perhaps it's fitting they do the same to our favorite baseball team too. After all, billionaires taking away any semblance of light at the end of the tunnel via their mere presence is the new American Dream.
Yahoo
28 minutes ago
- Yahoo
3 Supercharged Stocks Flashing Strong Momentum Signals
Several stocks have shown strong momentum in recent sessions as broader markets charge to all-time highs. Here's a look at some standout momentum movers that are just starting to pick up steam. 3 Momentum Names To Watch Benzinga's rankings system assigns scores to stocks based on momentum, growth, value and quality. The momentum score is a valuable metric for short-term trading strategies that aim to capture continuation of price trends. Identifying significant changes in momentum can help traders get ahead of potential changes in general stock direction. Benzinga's rankings system flagged three stocks that experienced significant changes in bullish momentum over the past week. BioXcel Therapeutics Inc (NASDAQ:BTAI) saw the biggest week-over-week jump in momentum score, moving from a score of 3.34 on Aug. 4 to a current score of 86.85. Shares of BioXcel Therapeutics, a biopharmaceutical company using AI to develop transformative medicines in neuroscience, have doubled over the past week and are up approximately 238% over the past month. BioXcel Therapeutics is currently trading well above its 50-day moving average of $2.11 and 100-day moving average of $1.92, indicating strong upward momentum. Key resistance is observed near the recent high of $7.36, while support can be identified around $6.67. Telos Corp (NASDAQ:TLS) also saw a strong surge in the momentum rankings this week, with a current score of 84.27, up from last week's score of 16.25. Multiple analysts lifted price targets ranging from $4 to $6 this week with shares up about 125% over the past five trading sessions. Telos is a provider of cyber, cloud and enterprise security solutions. The stock is currently trading well above its 50-day ($2.85), 100-day ($2.69) and 200-day ($3.02) moving averages, indicating a bullish trend and potential support levels at these averages. Jumia Technologies (NYSE:JMIA) saw its momentum score climb from 21.01 on Aug. 4 to 87.91 this week with shares up about 63% over the past week, according to Benzinga Pro. Jumia operates a pan-African e-commerce platform. The company is often referred to as the 'Amazon of Africa.' The stock is above its 50-day moving average of $4.22, indicating a bullish trend, while the 100-day and 200-day moving averages at $3.39 and $3.58, respectively, suggest strong support levels. Resistance is noted near the recent high of $7.85, which could act as a barrier for further upward movement. Price Actions: At the time of publication, BioXcel shares were down 12.65% at $5.94, while Telos shares were up 6.01% at $5.56 and Jumia shares were up 5.93% at $7.68, according to Benzinga Pro. Read Next: Bessent Wants Aggressive Fed Rate Cuts: 'We Should Be 150-175 Points Lower' Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet Photo: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article 3 Supercharged Stocks Flashing Strong Momentum Signals originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data